Navigation Links
Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
Date:1/30/2008

rt-acting anticoagulant effect. Under the agreement, Archemix is responsible for discovery of short-acting aptamers for use in medical procedures, and Nuvelo leads development and worldwide commercialization of these aptamers.

About Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Nuvelo's development pipeline includes alfimeprase, a direct acting fibrinolytic in Phase 2 clinical development for the treatment of thrombotic-related disorders including acute ischemic stroke and catheter occlusion; NU172, a direct thrombin inhibitor in Phase 1 development for use as a potential short-acting anticoagulant during medical or surgical procedures; and preclinical candidate NU206, a Wnt pathway modulator for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease . In addition, Nuvelo expects to continue its research programs in leukemia and lymphoma therapeutic antibodies and Wnt signaling pathway therapeutics to further expand its pipeline and create additional partnering and licensing opportunities.

Information about Nuvelo is available at our website at http://www.nuvelo.com or by phoning 650-517-8000.

This press release contains "forward-looking statements," which include statements regarding the timing and progress of Nuvelo's clinical stage and research programs, and the potential benefits that patients may experience from the use of our clinical stage compounds, which statements are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on our management's current expectations and involve risks and uncertainties. Actual results and performance could di
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
2. Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call
3. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
4. Northwestern Memorial Transplant Program Initiates New Study
5. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
6. SGX Initiates Phase I Trials for SGX523
7. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
8. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
9. Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure
10. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
11. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)DURHAM, N.C., Dec. 4 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) today announced that the first patient has been enrolled in the company,s Phase II-b, dose escalation, clinical trial in S
(Date:12/4/2009)ANNAPOLIS, Md., Dec. 4 PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, announced today the presentation of new d
(Date:12/4/2009)Opposes use of imported drugs often stored in tin cans and car trunks ,, WASHINGTON, Dec. 4 Today, the senior advocacy group RetireSafe urged the Senate to defeat the Dorgan Importation plan encomp
Breaking Medicine Technology:Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5RetireSafe Urges Senate to Defeat Senate Amendment 2793 -- Says Senator Dorgan's Drug Importation Plan Puts Seniors at Risk 2Linkwell Corporation Announces Launch of the Series of Handwashing Contest Across China 55285 1Linkwell Corporation Announces Launch of the Series of Handwashing Contest Across China 55285 2Linkwell Corporation Announces Launch of the Series of Handwashing Contest Across China 55285 3B Braun Named Supplier of the Year by McKesson 55284 1B Braun Named Supplier of the Year by McKesson 55284 2Hospice Foundation of America Presents New Educational Webinar on Supporting People with Intellectual Disabilities through Illness Grief and Loss 55282 1Hospice Foundation of America Presents New Educational Webinar on Supporting People with Intellectual Disabilities through Illness Grief and Loss 55282 2Hospice Foundation of America Presents New Educational Webinar on Supporting People with Intellectual Disabilities through Illness Grief and Loss 55282 3
...on six products from Pharmion,s pipeline provide s...ncluding promising Phase III,data on use of Thalid...ay 31, 2007 /PRNewswire-FirstCall/ -- Pharmion,Cor...s of studies,investigating the company,s marketed ...ed at the American Society of Clinical,Oncology,s ...
...ARY, June 01, 2007 /PRNewswire-FirstCall/ - Resear...colytics") are,scheduled to deliver a poster prese...t the American Society of Clinical Oncology,(ASCO)...ago. The,data cover final results of Oncolytics, U...oster, entitled "Final Results of a Phase I Study ...
Other Medicine Technology:Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 2Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 3Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 4Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 5Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 6Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 7Oncolytics Biotech Inc.'s Research Collaborators to Present,REOLYSIN Clinical Trial Data at ASCO Conference 2
(Date:12/5/2009)Research debunks the ,something,s wrong with being single, myth , , SATURDAY, Dec. 5 (HealthDay News) -- Pity the poor single people who pass their 40th birthday without ever tying the knot, s
(Date:12/4/2009)PALO ALTO, Calif., Dec. 4 Varian Medical Systems (NYSE: VAR ) announced today that its Board of Directors has set the regular 2010 Annual Meeting of Stockholders for February 11, 2010 with a record
(Date:12/4/2009)WASHINGTON, Dec. 4 The American Association of Homes and Services for the Aging (AAHSA) applauds the Senate for ensuring that the Community Living and Supportive Services (CLASS) provisions remain i
(Date:12/4/2009)WASHINGTON, Dec. 4 While Congress debates whether health care reform would control health care costs, Leapfrog,s purchaser members point to 45 hospitals that lead through example -- delivering the be
(Date:12/4/2009)Case Western Reserve University researchers, from the School of Medicine,s Department of Nutrition, discovered two new metabolic pathways by which products of lipid peroxidation and some drugs of abus
Breaking Medicine News(10 mins):Health News:Never Married, Over 40, Well-Adjusted 2Health News:Never Married, Over 40, Well-Adjusted 3Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2
...ield changes so rapidly that by the time students ...dical knowledge. //In an effort to address this is... Medicine adjusted its curriculum 13 years ago, an... skills beyond the medical licensing exam," said K...
...nts of funds Eden Medical Center a health affiliat...has finalized //its decision to call off its progr...rvices to Medi-Cal beneficiaries hitherto made ava...ther hospitals for specific services informed the ...
...ce with a drug called AZD2171 which reduced the s...ope // that it could someday soon be used in human...Research UK have been published in the journal Car...preventing tumours. Nearly 950,000 cases of ...
... therapy used to help reduce adverse events associ...e the risk of death for smokers admitted to// the ...d at CHEST 2006, the 72nd annual international sci...ent therapy (NRT) during their stay had a higher r...
...ll be able to do away with invasive breast reconst... stem cells //extracted from their own fat, sugges...estigating the potential these cells may have for ...roscopic scaffold structures will enable the produ...
...ption of beer and other alcohol beverages can play...he risk of several serious //diseases, including c...e disorders and osteoporosis, according to medical..., “Beer: To Your Health!” convened by the Universi...
Other Medicine News:Health News:Problem-Based Learning Curriculum a Success for Medical School 2Health News:Problem-Based Learning Curriculum a Success for Medical School 3Health News:Smoking Cessation Therapy May be Harmful for ICU Patients 2Health News:Breast reconstruction may be possible with fat stem cells 2Health News:Daily Moderate Consumption of Beer May be Healthy 2
Disposable Filter-Tips, 1100 l (960)
300 L Filter Barrier Pipette Tip
ART 250E
...otic Certified Tips for its full line of 96- and 3...he highest quality, PerkinElmer Robotic Certified ...led accuracy in high throughput applications. Tips...ume range from 0.5 L to 235 L. Tips for 384-channe...
Medicine Products: